vs
Anika Therapeutics, Inc.（ANIK）与GLAUKOS Corp（GKOS）财务数据对比。点击上方公司名可切换其他公司
GLAUKOS Corp的季度营收约是Anika Therapeutics, Inc.的4.7倍（$143.1M vs $30.6M）。Anika Therapeutics, Inc.净利率更高（1.0% vs -93.4%，领先94.3%）。GLAUKOS Corp同比增速更快（35.7% vs 0.0%）。Anika Therapeutics, Inc.自由现金流更多（$4.0M vs $3.9M）。过去两年GLAUKOS Corp的营收复合增速更高（29.3% vs 2.7%）
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
ANIK vs GKOS — 直观对比
营收规模更大
GKOS
是对方的4.7倍
$30.6M
营收增速更快
GKOS
高出35.6%
0.0%
净利率更高
ANIK
高出94.3%
-93.4%
自由现金流更多
ANIK
多$60.0K
$3.9M
两年增速更快
GKOS
近两年复合增速
2.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $30.6M | $143.1M |
| 净利润 | $292.0K | $-133.7M |
| 毛利率 | 62.6% | -1.1% |
| 营业利润率 | 2.1% | -97.7% |
| 净利率 | 1.0% | -93.4% |
| 营收同比 | 0.0% | 35.7% |
| 净利润同比 | 101.3% | -298.0% |
| 每股收益（稀释后） | $0.02 | $-2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIKGKOS
| Q4 25 | $30.6M | $143.1M | ||
| Q3 25 | $27.8M | $133.5M | ||
| Q2 25 | $28.2M | $124.1M | ||
| Q1 25 | $26.2M | $106.7M | ||
| Q4 24 | $30.6M | $105.5M | ||
| Q3 24 | $29.6M | $96.7M | ||
| Q2 24 | $30.7M | $95.7M | ||
| Q1 24 | $29.0M | $85.6M |
净利润ANIKGKOS
| Q4 25 | $292.0K | $-133.7M | ||
| Q3 25 | $-2.3M | $-16.2M | ||
| Q2 25 | $-4.0M | $-19.7M | ||
| Q1 25 | $-4.9M | $-18.1M | ||
| Q4 24 | $-21.9M | $-33.6M | ||
| Q3 24 | $-29.9M | $-21.4M | ||
| Q2 24 | $-88.0K | $-50.5M | ||
| Q1 24 | $-4.5M | $-40.8M |
毛利率ANIKGKOS
| Q4 25 | 62.6% | -1.1% | ||
| Q3 25 | 56.0% | 78.4% | ||
| Q2 25 | 50.9% | 78.3% | ||
| Q1 25 | 56.1% | 77.2% | ||
| Q4 24 | 56.0% | 72.9% | ||
| Q3 24 | 65.7% | 76.6% | ||
| Q2 24 | 66.7% | 76.4% | ||
| Q1 24 | 65.4% | 76.3% |
营业利润率ANIKGKOS
| Q4 25 | 2.1% | -97.7% | ||
| Q3 25 | -11.6% | -12.3% | ||
| Q2 25 | -14.8% | -18.3% | ||
| Q1 25 | -16.4% | -19.4% | ||
| Q4 24 | -2.3% | -27.2% | ||
| Q3 24 | -0.3% | -25.5% | ||
| Q2 24 | -5.9% | -31.3% | ||
| Q1 24 | -8.6% | -45.6% |
净利率ANIKGKOS
| Q4 25 | 1.0% | -93.4% | ||
| Q3 25 | -8.4% | -12.2% | ||
| Q2 25 | -14.1% | -15.8% | ||
| Q1 25 | -18.6% | -17.0% | ||
| Q4 24 | -71.4% | -31.8% | ||
| Q3 24 | -101.2% | -22.1% | ||
| Q2 24 | -0.3% | -52.8% | ||
| Q1 24 | -15.6% | -47.7% |
每股收益（稀释后）ANIKGKOS
| Q4 25 | $0.02 | $-2.34 | ||
| Q3 25 | $-0.16 | $-0.28 | ||
| Q2 25 | $-0.28 | $-0.34 | ||
| Q1 25 | $-0.34 | $-0.32 | ||
| Q4 24 | $-1.49 | $-0.56 | ||
| Q3 24 | $-2.03 | $-0.39 | ||
| Q2 24 | $0.00 | $-1.00 | ||
| Q1 24 | $-0.31 | $-0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $81.2M | $90.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $143.5M | $656.2M |
| 总资产 | $190.3M | $893.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIKGKOS
| Q4 25 | $81.2M | $90.8M | ||
| Q3 25 | $80.2M | $98.2M | ||
| Q2 25 | $77.1M | $100.8M | ||
| Q1 25 | $75.4M | $114.3M | ||
| Q4 24 | $79.2M | $169.6M | ||
| Q3 24 | $90.7M | $100.1M | ||
| Q2 24 | $96.6M | $68.1M | ||
| Q1 24 | $100.7M | $42.5M |
股东权益ANIKGKOS
| Q4 25 | $143.5M | $656.2M | ||
| Q3 25 | $146.8M | $769.5M | ||
| Q2 25 | $147.7M | $765.1M | ||
| Q1 25 | $148.4M | $764.0M | ||
| Q4 24 | $154.0M | $766.9M | ||
| Q3 24 | $179.9M | $668.5M | ||
| Q2 24 | $210.3M | $665.2M | ||
| Q1 24 | $208.5M | $450.7M |
总资产ANIKGKOS
| Q4 25 | $190.3M | $893.5M | ||
| Q3 25 | $189.4M | $999.4M | ||
| Q2 25 | $187.7M | $987.0M | ||
| Q1 25 | $190.6M | $966.2M | ||
| Q4 24 | $202.7M | $974.8M | ||
| Q3 24 | $231.4M | $926.5M | ||
| Q2 24 | $262.7M | $919.7M | ||
| Q1 24 | $263.7M | $933.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.6M | $6.8M |
| 自由现金流经营现金流 - 资本支出 | $4.0M | $3.9M |
| 自由现金流率自由现金流/营收 | 13.0% | 2.7% |
| 资本支出强度资本支出/营收 | 2.1% | 2.0% |
| 现金转化率经营现金流/净利润 | 15.88× | — |
| 过去12个月自由现金流最近4个季度 | $4.4M | $-22.5M |
8季度趋势，按日历期对齐
经营现金流ANIKGKOS
| Q4 25 | $4.6M | $6.8M | ||
| Q3 25 | $6.9M | $-10.1M | ||
| Q2 25 | $-189.0K | $7.0M | ||
| Q1 25 | $-130.0K | $-18.5M | ||
| Q4 24 | $1.6M | $507.0K | ||
| Q3 24 | $5.0M | $-9.6M | ||
| Q2 24 | $-1.1M | $-18.4M | ||
| Q1 24 | $-126.0K | $-33.9M |
自由现金流ANIKGKOS
| Q4 25 | $4.0M | $3.9M | ||
| Q3 25 | $5.0M | $-11.7M | ||
| Q2 25 | $-1.7M | $5.8M | ||
| Q1 25 | $-3.0M | $-20.5M | ||
| Q4 24 | $275.0K | $-1.2M | ||
| Q3 24 | $3.8M | $-11.0M | ||
| Q2 24 | $-4.5M | $-20.5M | ||
| Q1 24 | $-1.9M | $-34.8M |
自由现金流率ANIKGKOS
| Q4 25 | 13.0% | 2.7% | ||
| Q3 25 | 17.9% | -8.8% | ||
| Q2 25 | -5.9% | 4.7% | ||
| Q1 25 | -11.3% | -19.2% | ||
| Q4 24 | 0.9% | -1.2% | ||
| Q3 24 | 12.9% | -11.4% | ||
| Q2 24 | -14.6% | -21.4% | ||
| Q1 24 | -6.7% | -40.7% |
资本支出强度ANIKGKOS
| Q4 25 | 2.1% | 2.0% | ||
| Q3 25 | 6.8% | 1.2% | ||
| Q2 25 | 5.2% | 0.9% | ||
| Q1 25 | 10.8% | 1.8% | ||
| Q4 24 | 4.3% | 1.6% | ||
| Q3 24 | 4.1% | 1.5% | ||
| Q2 24 | 11.1% | 2.2% | ||
| Q1 24 | 6.2% | 1.1% |
现金转化率ANIKGKOS
| Q4 25 | 15.88× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIK
| OEM Channel | $17.3M | 57% |
| Commercial Channel | $13.3M | 43% |
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
